Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial

Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the growth stocks that could double by 2027. On June 25, the company announced positive topline results from its Phase 1b trial of ABI-4334, a capsid assembly modulator for the treatment of chronic hepatitis B.

Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial

A scientist in a white lab coat working at a bench with biopharmaceutical equipment.

The 28-day study showed HBV DNA reductions of 2.9 log10 IU/mL at 150 mg and 3.2 log10 IU/mL at 400 mg, with additional declines in HBV RNA. The lower dose achieved saturated inhibition of viral replication, while the higher dose may enhance suppression of cccDNA formation, a key viral reservoir.

The drug was well-tolerated, with no serious adverse events and pharmacokinetics supporting once-daily oral dosing. These results activate a licensing decision for Gilead Sciences, which holds rights to further develop ABI-4334.

Assembly Biosciences, Inc. is a clinical-stage biotech focused on small-molecule therapies for serious viral infections. Its pipeline includes candidates for hepatitis B, hepatitis delta, herpesviruses, and transplant-related infections. The company collaborates with Gilead Sciences to advance next-generation antiviral treatments.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

This article is originally published at Insider Monkey.